Edition:
United States

CytRx Corp (CYTR.A)

CYTR.A on American Stock Exchange

2.75USD
22 Sep 2015
Change (% chg)

-- (--)
Prev Close
$2.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
--
52-wk Low
--

Select another date:

BRIEF-Cytrx reports loss per share of $0.27 for Q2 2016

* Q2 loss per share $0.27 Source text for Eikon: Further company coverage:

BRIEF-CVI Investments reports 7.5 pct passive stake in Cytrx as of July 15

* CVI Investments reports 7.5 pct passive stake in Cytrx as of July 15 - SEC filing Source text (http://bit.ly/2aAKZQa) Further company coverage: (Bengaluru Newsroom : +1-646-223-8780)

BRIEF-Cytrx Corp announces pricing of $20 mln public offering

* Cytrx Corp announces pricing of $20 million public offering of common stock and warrants

BRIEF-CytRx reports initial results of aldoxorubicin late-stage trial in soft tissue sarcoma patients

July 11 Cytrx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second

BRIEF-CytRx reports Q1 loss per share $0.19

* Q1 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Cytrx to present new clinical data on its cancer drug

* Cytrx to present updated aldoxorubicin clinical trial data at the American Society of Clinical Oncology Annual Meeting in June 2016 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Cytrx presents aldoxorubicin phase 3 clinical trial data

* Cytrx global pivotal phase 3 clinical trial with aldoxorubicin achieves 191 target events triggering statistical data analysis

Select another date: